Street Calls of the Week
Director Jones James of Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), a small-cap pharmaceutical company valued at $51.31 million, has been actively purchasing company stock, according to a recent Form 4 filing. The stock has shown remarkable strength with a 164% gain over the past year, despite recent volatility. Between August 1, 2025, and August 29, 2025, Jones acquired a total of $861 worth of Cumberland Pharmaceuticals shares.
The purchases were executed at prices ranging from $2.84 to $4.01. Specifically, Jones bought shares in 21 separate transactions, each for 13 shares, with one transaction for 2 shares.
Following these transactions, Jones directly owns 43,938 shares of Cumberland Pharmaceuticals Inc. For deeper insights into CPIX’s valuation and growth potential, investors can access comprehensive analysis through InvestingPro, which offers exclusive financial metrics and expert research reports.
In other recent news, Cumberland Pharmaceuticals Inc. reported its second quarter 2025 earnings, showcasing a revenue increase of 10% year-over-year, reaching $10.8 million. However, the company’s earnings per share (EPS) did not meet analysts’ expectations, resulting in a loss of $0.02. This earnings miss has been a point of concern for investors. Analysts had projected a different outcome, and the shortfall has contributed to recent discussions about the company’s financial health. Despite the revenue growth, the company’s stock has experienced volatility, trading near the lower end of its 52-week range. There have been no recent reports of mergers or acquisitions involving Cumberland Pharmaceuticals. Additionally, no analyst upgrades or downgrades have been noted in the latest updates. These developments are crucial for investors monitoring the pharmaceutical company’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.